A case of hepatocarcinoma treated as part of a randomized phase III trial with tremelimumab (anti-CTLA-4) followed by durvalumab (anti-PD-L1) every 4 weeks is reported in the literature; in this case, biopsy taken after treatment showed the presence of neuroendocrine carcinoma; the authors conclude that it could represent a documented event of neuroendocrine transition in the context of HCC [71]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.